Simultaneous expression of steroid sulfatase and androgen receptor reduced overall survival of patients with epithelial ovarian tumors

Argelia Calvillo-Robledo1, Enrique Pedernera2, Flavia Morales-Vásquez2, Delia Pérez-Montiel3, María J. Gómora2, Miguel Ángel Almaraz2, Paulina García de Alba Graue2, Elizabeth Rendón4, Horacio Noé López-Basave3, Andrés Quintanar-Stephano1* and Carmen Méndez2*

Abstract

Background: Ovarian cancer is usually diagnosed at an advanced stage due to its early asymptomatic course and late-stage non-specific symptoms. This highlights the importance of researching the molecular mechanisms involved in ovarian carcinogenesis as well as the discovery of novel prognostic markers that could help improve the survival outcome of patients. The aim of this study was to evaluate the expression of the steroid sulfatase (STS) in 154 samples of primary ovarian tumors. This protein is crucial in the intracellular conversion of sulfated steroid hormones to active steroid hormones. The presence of STS, 3β-HSD, and 17β-HSD1 result in the production of testosterone which act through the androgen receptor (AR) in the tumor cell. The presence of STS and AR in epithelial ovarian tumors and their association to the overall survival of patients was evaluated using Kaplan–Meier and Cox regression analyses.

Results: Immunoreactivity for STS was detected in 65% of the tumors and no association was observed with histological subtypes and clinical stages of the tumor. The STS expression in the tumors exhibiting immunoreactive AR resulted in a reduced survival (log-rank test, \(p = 0.032\)) and a risk factor in univariate and multivariate analysis, \(HR = 3.46, CI_{95\%} = 1.00–11.92, p = 0.049\) and \(HR = 5.92, CI_{95\%} = 1.34–26.09, p = 0.019\), respectively.

Conclusions: These findings suggest that the intracellular synthesis of testosterone acting through its receptor can promote tumor growth and progression. Moreover, the simultaneous expression of STS and AR constitutes an independent predictor of poor prognosis in epithelial ovarian tumors.

Keywords: Epithelial ovarian tumor, Ovarian cancer, Steroid sulfatase, Androgens, Androgen receptor

Background

Ovarian cancer (OC) is the eighth most common cancer in women and the second leading cause of death related to gynecological tumors worldwide [1]. Ovarian cancer typically affects postmenopausal women. They are usually diagnosed at an advanced stages of the disease, due to its early asymptomatic course and late-stage non-specific symptoms such as pelvic pain, gastrointestinal symptoms or bloating. In addition, the recurrence of the disease often occurs within 2 years after diagnosis with high resistance to chemotherapy [2].

Epithelial ovarian cancer (EOC) represents more than 90% of diagnosed ovarian tumors and it is a complex and heterogeneous disease at molecular, genetic and histological levels [3]. The main histological subtypes are...
high grade serous carcinoma (HGSC), low grade serous carcinoma (LGSC), endometrioid, mucinous, and clear cells carcinoma. The epidemiology of EOC is linked to hormonal and reproductive events such as early age at menarche, older age at menopause, and hormone replacement therapy increase the risk of developing EOC, while pregnancy, use of hormone contraception, and prolonged lactation are protective factors [4].

The presence of steroid hormone receptors and their ligands in tumor tissue have been associated to proliferation and epithelium-mesenchymal transition (EMT) in ovarian cancer [5]. Progesterone receptor expression has been previously associated to improved survival outcome in HGSC patients, whereas progesterone and estrogen receptors alone or in combinations result in a best prognosis in patients with endometrioid carcinoma [6]. Moreover, it has been suggested that the enzymes involved in estrogen synthesis could be associated to cell proliferation in several types of cancers, such as endometrial and ovarian cancer [7, 8].

Epidemiological and experimental evidence suggest the involvement of androgens in the development of ovarian tumors [9, 10]. Ose et al. and Trabert et al. observed circulating androgens levels are associated with an increased risk of developing endometrioid and mucinous ovarian carcinoma [11, 12]. However, the role of the androgen receptor in overall survival in EOC patients is still inconclusive, although previous studies have reported that an increased androgen receptor expression is associated with an improved survival [13] other studies have described the absence of any significant association between steroid receptor expression and overall survival [14].

Sulfated steroids like dehydroepiandrosterone sulfate (DHEA-S) from adrenal origin and estrone sulfate (E1-S) are found in high levels in plasma of premenopausal and postmenopausal women [15]. The intracellular presence of the steroid sulfatase (STS) in peripheral tissue allows to obtain active forms of DHEA and E1 which are converted into potent testosterone and 17β-estradiol [16]. The presence and significance of STS has been evaluated in both, normal and cancerous breast tissue [17]. However, the importance of sulfated steroids and steroid sulfatase has been less explored in ovarian cancer and thus the involvement of the enzyme on patient survival remains controversial [18–20].

The goal of the present study is to determine the expression profile of steroid sulfatase (STS), and the androgen receptor (AR) in the serous, endometrioid and mucinous histological subtypes of ovarian tumors in order to provide evidence of their relevance as a risk factor in overall patient survival.

Results

The histological subtypes of the tumors included in the study were as follows: borderline tumors (BT) 27/154 (18%), low grade serous carcinomas 16/154 (10%), high grade serous carcinomas 44/154 (29%), endometrioid carcinoma 35/154 (23%), mucinous carcinoma 16/154 (10%), clear cells carcinoma 6/154 (4%) and 6% of another tumor subtype. The clinical features of the patients were summarized by the age at diagnosis, the reproductive status, the clinical stages of the tumor according to the FIGO scale, the histological grade registered for endometrioid carcinoma and the success of surgery (Table 1).

Immunofluorescence and immunohistochemistry reactions showed that steroid sulfatase (STS) was located in the cytoplasm of epithelial tumor cells displaying a distribution similar to cytokeratins, whereas the androgen receptor (AR) was identified in the nucleus of tumor epithelium (Fig. 1).

Frequency of expression of steroid sulfatase and androgen receptor

STS was detected in 65% of the tumors. No association was observed between the expression of STS and the histological subtypes of the tumors (p = 0.20) or between the expression of STS and the clinical stage (p = 0.84) (Tables 2 and 3).

The androgen receptor was detected in the nucleus of epithelial tumor cells in 58% of the samples. However, there was no association found between the expression of the androgen receptor to the histological subtypes (p = 0.39) or the clinical stage (p = 0.96). When comparing serous versus non-serous subtypes, we observed a higher frequency of AR expression in serous subtypes (p = 0.05) (Tables 2 and 3).

Patients overall survival related to steroid sulfatase and androgen receptor expression

The survival curves obtained by Kaplan–Meier analysis displayed in Fig. 2A showed that the presence of STS in epithelial ovarian tumors is related to a reduced survival of patients (log-rank test, p = 0.032), whereas the presence of androgen receptor did not modify the patients’ survival during the 6-years follow-up (Fig. 2B).

Based on Cox proportional hazards regression model the age at diagnosis, the clinical stage (FIGO III and IV), and a suboptimal debulking surgery showed a significant increase in hazard ratio (HR) values in univariate analysis; whereas STS and androgen receptor presence HR values were not significant. In the multivariate analysis, considering age and clinical stage as covariates, HR values for STS and AR remained non-significant, p = 0.08 and 0.68, respectively (Table 4).
Co-expression of steroid sulfatase and androgen receptor on patient overall survival

The total of the patients included in the study were stratified considering the presence or absence of AR in the ovarian tumor evaluating their overall survival. The survival curves demonstrated that the presence of STS represents a worse prognosis for the patients with AR positive tumors ($p=0.011$); whereas in AR negative tumors, STS
expression did not modify the overall survival of patients \((p=0.998)\) (Fig. 3). The proportional hazard regression analysis displayed the following values for STS in AR positive tumors: \(HR = 3.46, 95\% CI 1.00–11.92, p=0.049\) and \(HR = 5.92, 95\% CI 1.34–26.09, p=0.019\) univariate and multivariate analysis, respectively. The HR values in AR negative tumors were not significant (Table 5).

Table 2 Frequency of STS and AR expression by histological subtype

| Enzyme or Receptor | SBT | LGSC | HGSC | Endometrioid | Mucinous | \(P\)-value |
|--------------------|-----|------|------|--------------|----------|------------|
| STS                | 17/26 (65) | 7/16 (43) | 31/44 (70) | 21/35 (60) | 13/16 (81) | 0.203      |
| AR                 | 19/27 (70) | 11/16 (69) | 26/44 (59) | 17/35 (49) | 8/16 (50)  | 0.388      |

Absolute values (percentage), \(P\)-value, Chi-square analysis

STS Steroid sulfatase, AR Androgen receptor, SBT Serous borderline tumors, LGSC Low grade serous carcinoma, HGSC High grade serous carcinoma

Table 3 Association between STS and AR expression with the clinical grades of ovarian tumors

| Enzyme or Receptor | ECI  | ECII | ECIII | ECIV | \(P\)-value |
|--------------------|------|------|-------|------|------------|
| STS                | 38/63 (60) | 7/10 (70) | 34/53 (64) | 10/14 (71) | 0.838      |
| AR                 | 38/63 (60) | 6/10 (60) | 30/54 (56) | 8/14 (58)  | 0.962      |

Absolute values (percentage), \(P\)-value, Chi-square analysis

STS Steroid sulfatase, AR Androgen receptor

![Fig. 2 Kaplan–Meier analysis of overall survival of patients associated to the expression of A steroid sulfatase and B androgen receptor. The survival curve is lower in patients that express STS. \(P<0.05\)](image)

Table 4 Cox proportional regression analysis

| Variables | Univariate | Multivariate |
|-----------|------------|--------------|
|           | HR         | 95\% CI      | \(p\)-value | HR         | 95\% CI      | \(p\)-value |
| STS       | 2.032      | 0.83–4.96    | 0.119      | 2.435      | 0.91–6.48    | 0.075      |
| AR        | 1.126      | 0.53–2.35    | 0.753      | 1.170      | 0.55–2.48    | 0.681      |
| Age       | 1.035      | 1.00–1.06    | 0.009      | 1.025      | 0.99–1.05    | 0.105      |
| FIGO      |            |              |           |            |              |           |
| II        | 3.551      | 0.32–2.93    | 0.301      | 3.330      | 0.30–36.79   | 0.326      |
| III       | 12.785     | 2.93–56.72   | \(<0.001\) | 12.267     | 2.79–53.84   | \(<0.001\) |
| IV        | 26.390     | 5.69–122.3   | \(<0.001\) | 20.102     | 4.24–95.22   | \(<0.001\) |
| Surgery   | 5.015      | 2.16–11.64   | \(<0.001\) | –          | –            | –          |

\(HR\) Hazard ratio, STS Steroid sulfatase, AR Androgen receptor, FIGO International Federation of Gynecology and Obstetrics
The present retrospective study demonstrates that the simultaneous expression of STS and AR in epithelial ovarian tumors reduced overall survival of the patients. This information was obtained from tumor samples collected at the diagnostic surgery in patients who had not undergone neoadjuvant therapy. The presence of STS and AR was demonstrated following an immunohistochemistry and immunofluorescence protocol and represents an accessible and relatively inexpensive methodology to characterize the tumor.

Results reported herein demonstrate that STS was present in 68% of the ovarian tumors, a frequency similar to that previously described in clear cells ovarian carcinoma [18], with the enzyme being localized in the cytoplasm of epithelial tumor cell, as previously shown by immunohistochemistry in epithelial ovarian cancer [18, 20]. Similarly, sulfatase activity has been demonstrated in tumors of the female reproductive system and corroborated in ovarian cancer samples by the incubation of tissue homogenates with estrone sulfate isotopes by evaluating estrone and 17β-estradiol formation [19, 21].

The presence of STS was not associated with the FIGO stage of the tumor, and a similar finding was demonstrated when comparing to the clinical stage in clear cells ovarian carcinoma [18]. The relationship of STS to the histological subtype of ovarian tumor was not statistically significant in the present study. Variations between subtypes should be considered in subsequent extensive studies of epithelial ovarian tumors.

Overall survival curves obtained through Kaplan–Meier analysis displayed a poor survival rate in STS positive tumors, however, this finding was not corroborated by a strong analysis like Cox proportional hazard regression. A previous study reported that patients with a tumor tissue displaying high sulfatase activity had a reduction in progression-free survival but the overall survival remained unchanged [18]. A similar absence of overall survival reduction was described by Mungenast et al. [20] in ovarian cancer. Further studies are needed in order to demonstrate that survival of patients could be affected by the expression of STS in ovarian tumors.

In the present study, a worse overall survival related to STS expression was demonstrated by Kaplan–Meier and Cox regression analyses in patients with AR positive tumors, however, this finding was not corroborated by a strong analysis like Cox proportional hazard regression. A previous study reported that patients with a tumor tissue displaying high sulfatase activity had a reduction in progression-free survival but the overall survival remained unchanged [18]. A similar absence of overall survival reduction was described by Mungenast et al. [20] in ovarian cancer. Further studies are needed in order to demonstrate that survival of patients could be affected by the expression of STS in ovarian tumors.

Table 5 Cox regression analysis of steroid sulfatase based on the presence of androgen receptor

| Expression       | Univariate | Multivariate |
|------------------|------------|--------------|
|                  | HR         | 95% CI       | p-value | HR         | 95% CI       | p-value |
| STS /AR (+)      | 3.463      | 1.00–11.92   | 0.049   | 5.917      | 1.34–26.09   | 0.019   |
| STS /AR (-)      | 0.766      | 0.19–2.94    | 0.697   | 1.033      | 0.19–5.49    | 0.970   |

HR Hazard ratio, STS Steroid sulfatase, AR Androgen receptor
their receptor can promote carcinogenesis [24]. Alternatively, DHEA-S via aromatase pathway and estrone-sulfate are transformed to estrone and 17β-estradiol which favor the tumor growth [25]. Another possibility to be considered is the combined action of both androgens and estrogens in ovarian tumors, through which the presence of receptors and their active ligands will stimulate, angio genesis, cell proliferation, epithelial-mesenchymal transition, migration, invasion, and metastasis, acting directly or through growth factors and cytokines.

Conclusions
In conclusion, our results demonstrate that the simultaneous expression of steroid sulfatase and the androgen receptor at the time of diagnosis of epithelial ovarian tumors reduced overall patient survival and constitutes an independent prognostic factor that maybe taken into consideration when conducting the clinical evaluation and treatment plan of patients. While, further knowledge about the role of these proteins in ovarian tumors is needed, the results obtained in the present study constitute a solid base of significant data for the use in targeted treatments of patients diagnosed with this malignancy.

Methods
Samples and patients
The study group comprised 154 samples of patients with pathological diagnosis of primary ovarian tumor from the Military Hospital for Women's Specialties and Neonatology, SEDENA (Mexico's Defense Ministry), and the National Institute of Cancerology in Mexico City spanning a time period of 10 years between 2008 and 2018. Written consent was obtained from each patient in order to participate in this study, none of whom had received chemotherapy or radiotherapy prior to surgery, per inclusion criteria. The tissue processing was done in accordance with the protocols established for international tumor banks and was approved by the Ethics Committee of the School of Medicine of the National Autonomous University of Mexico (UNAM-108/2015) as well as the Military Hospital of Women's Specialties and Neonatology (310–18) and the National Institute of Cancerology (INCan) (019/060/OMI).

Immunohistochemistry
The study samples were obtained through intraoperative biopsy for diagnosis by the pathology department, after which whole sections of paraformaldehyde-fixed and paraffin-embedded tissue samples were serial sectioned at 3 μm thickness and placed on coated glass slides (Biocare Medical, Pacheco, CA, USA) which were deparaffinized by incubation in xylol and rehydrated through graded concentrations of ethanol, with the antigens being retrieved with Diva Decloaker citrate buffer (Biocare Medical) in a pressurized cooker at 110 °C for 15 min. Endogenous peroxidase was blocked by hydrogen peroxide at 1% H2O2 for 10 min. (Biocare Medical) after rising in PBS (pH 7.3) incubating the slides overnight at 4 °C with the following polyclonal rabbit primary antibody to AR, diluted 1:50 (Sc816, Santa Cruz Biotechnology, Santa Cruz, CA), using Mach2 anti-rabbit HRP as a secondary antibody for 1 h at room temperature (Biocare Medical) and signal detection was achieved using a diaminobenzidine chromogen kit (DAB) (Biocare Medical). The negative controls were tissue samples in which the primary antibody was substituted with PBS including the positive control tissues (placenta for STS and mice testis for AR) as well in each immune reaction, rinsing the slides with water after counterstaining them with hematoxylin. To assess the positivity ratio of reactions we evaluated the intensity of the staining and the percentage of labeled cells in the tissue samples. Thus the samples with no noticeable staining were rated as 0, while cells exhibiting a light staining were labeled as 1, cells with a moderate staining were marked as 2, and cells with a strong staining were designated as 3. The percentage of labeled cells was considered as: 1 = 10–25%, 2 = 26–50%, 3 = 51–80%, and 4 = 80%. Positive reaction was considered whenever the index obtained from multiplying intensity and percentage was ≥ 2. Sample analyses were performed by three independent observers (MJG, MAA, and EP).

Immunofluorescence
Slides were incubated overnight at room temperature with the following polyclonal rabbit primary antibodies: anti-STS, diluted 1:200 (GTX105498, GeneTex, Inc.) and further incubated with a secondary antibody goat-anti-rabbit Alexa 488, diluted 1:1000 (Thermo Fisher Scientific, Waltham, MA, USA). In order to identify epithelial cells, the slides were secondarily incubated overnight at 4 °C, with mouse monoclonal anti pan-cytokeratin AE1/AE3+8/18, diluted 1:1000 (CM162C, Biocare Medical). The samples were washed with PBS and incubated with the secondary antibody Alexa Fluor 647 donkey antimouse, diluted 1:500 (A31571, Thermo Fisher Scientific). Placenta was used as a positive control in each immune reaction. The nucleus was stained with 4′, 6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) (Sigma-Aldrich, Inc). The slides were mounted with VectaShield mounting medium (Vector Laboratories) and the immunolabeled slices were observed by confocal laser microscope Leica TCS SP5 (Leica Microsystems, Wetzlar, Germany) using excitation spectral laser lines at 488 and 647 nm.
Statistical analysis
Association between variables was analyzed by Pearson’s Chi square, to determine the hazard ratio considering every possible variable we performed multivariate analysis using Cox regression model and calculated the overall survival rate through Kaplan–Meier analysis evaluating all significant data using SPSS 21.0 statistical software. Differences were considered significant at p < 0.05.

Acknowledgements
We are grateful to Mrs. Angelica Caballero for her technical assistance and Mr. Esteban Mena for his help with the database.

Authors’ contributions
ACR: Development of methodology and performing the experiments, and data analysis, writing of the original manuscript draft. EP: Formulation of research ideas and objectives, critical review and revision of the manuscript. FMV: Formulation of research ideas and objectives, critical review and revision of the manuscript. MUG, PGDAG: Development of methodology, performing the experiments and statistical analysis of data. MAA: Collection of data, management of dataset and formal data analysis. DFM, ER: Histopathology study of tumor samples. HNLB: Selection of patients and clinical outcome validation. AQS: design of methodology, critical review and revision of the manuscript, coordination of research activity, CM: Formulation of research ideas and aims, design of methodology, critical review and revision of the manuscript, coordination of research activity. All authors read and approved the final manuscript.

Funding
The present work was supported by a grant from DGAPA-PAPIIT, IN218120 to CM and DGAPA-PAPIIT, IN221219 to EP; ACR is supported by a CONACYT and approved the final manuscript.

Availability of data and materials
The dataset used and/or analyzed during the current study are available from the corresponding authors on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the ethical committees of INCan (019/060/OMI), Military Hospital of Women’s Specialties and Neonatology (310–18) and UNAM (FM/DI/108/2015).

Consent for publication
Non applicable.

Competing interests
The authors declare no competing interests.

Author details
1 Departamento de Fisiología, Centro de Ciencias Básicas, Universidad Autónoma de Aguascalientes, Av. Universidad No. 940, C. D. Universitaria, Aguascalientes, AG-C.P. 20131, México. 2 Departamento de Embriología y Genética, Facultad de Medicina, Universidad Nacional Autónoma de México, Av. Universidad. 3000, Ciudad de México C.P. 04510, México. 3 Instituto Nacional de Cancerología, Secretaría de Salud de México, Ciudad de México, México. 4 Hospital Militar de Especialidades de la Mujer y Neonatología, Secretaría de la Defensa Nacional, Ciudad de México, México.

Received: 9 March 2021    Accepted: 25 June 2021
Published online: 29 July 2021

References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;0:1–41.
2. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502–6.
3. Kurman RJ, Shih IM. Molecular pathogenesis and extratradional origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011;42:918–31.
4. Jonsson J-M, Skovbjerg & Arildsen N, Malander S, Mååbäck A, Hartman L, Nilbert M, Hedenfalk I. Sex steroid hormone receptor expression affects ovarian cancer survival. Transl Oncol. 2015;8:424–33.
5. de Almeida Chuffa LG, Lupi ‑Júnior LA, Costa AB, de Arruda Amarim JP, Seva FRF. The role of sex hormones and steroid receptors on female reproductive cancers. Steroids. 2017;118:93–108.
6. Sieh W, Köbel M, Longacre TA, Botvill DL, de芳zio A, Goodman MT, Hagdall E, Deen S, Wentzensen N, Moyaish K, Brenton JD, Clarke BA, Menon U, Giles CB, Kim A, Madoro J, Feerdawy S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjaer SK, Jensen A, Hagdall C, Kalli KR, Fridley BL, Keyney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, Garcia‑Closas M, Lissowska J, Doudani K, Morrison C, Lele S, Bhatia W, Sucheston L, Jimenez‑Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MG, Mackay H, Oza A, Wozniak‑EL, Benjamin E, Gentry‑Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Angeličko MS, Johnatty SE, Chenewix‑Trench G, Whitemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ. Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study. Lancet Oncol. 2013;14:853–62.
7. Ren X, Wu X, Hillier SG, Fegan KS, Crichtley HO, Mason JL, Sarvi S, Haflow CR. Local estrogen metabolism in epithelial ovarian cancer suggests novel targets for therapy. J Steroid Biochem Mol Biol. 2015;150:54–63.
8. RzhezTL. The important roles of steroid sulfatase and sulfotransferases in gynecological diseases. Front Pharmacol. 2016;7:30.
9. Heldszkewski KJ, Alberge AJ, Gordon GB, Longcope C, Bitoil LW, Hoffman SC, Comstock GW. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA. 1995;274:1926–30.
10. Lukanova A, Lundin E, Akhmedikhanov A, Micheli A, Rinaldi S, Zeleniuch‑Jacquotte A, Lenner P, Murti P, Biessy C, Krogh V, Berrino F, Hallmans G, Riboli E, Kaaks R, Toniolo P. Circulating levels of sex steroid hormones and risk of ovarian cancer. Int J Cancer. 2003;104:636–42.
11. Ose J, Poode EM, Schock H, Lehrten M, Ansan AA, Zeleniuch‑Jacquotte A, Vivasanathan K, Heldszkewski KJ, Ee LM, Tannieland A, Dossus L, Trichopoulou A, Massala G, Onland‑Moret NC, Weiderpass E, Duell EJ, Ichihara A, Travis RC, Rinaldi S, Merritt MA, Trabert B, Wentzensen N, Tworoger SS, Kaaks R, Fornter RT. Androgens are differentially associated with ovarian cancer subtypes in the Ovarian Cancer Cohort Consortium. Cancer Res. 2017;77:3951–60.
12. Trabert B, Michels KA, Anderson GL, Brinton LA, Falk RT, GecziK AM, Harris HR, Pan K, Pfeiffer MM, Qi L, Rohan T, Wentzensen N, Xu X. Circulating androgens and postmenopausal ovarian cancer risk in the women’s health initiative observational study. Int J Cancer. 2019;145:2051–120.
13. Nodin B, Zendeheorh K, Brändstedt J, Nilsson E, Manjer J, Brennan DJ, Jnrtom K. Increased androgen receptor expression in serious carcinoma of the ovary is associated with an improved survival. J Ovarian Res. 2010;3:14.
14. de Toledo MC, Sarian LO, Sallum LF, Andrade LL, Vassallo J, de Paiva Silva GR, Pinto GA, Soares FA, Fonseca CD, Derchain SF. Analysis of the "triple‑negative" tumor status to disease‑free and overall survival of women with epithelial ovarian cancer. Acta Histochem. 2014;16:440–7.
15. Labrie F, Bellanger A, Luca‑The V, Labrie C, Simard J, Cusian L, Gomez JL, Canudas B. DHEA and the intracellular formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids. 1998;63:322–8.
16. Geyer J, Bakhuis K, Bernhardt R, Blascica C, Dezcham Y, Fiertz D, Grosser G, Hartmann K, Hartmann MF, Neurzig J, Papadopoulos D, Sánchez‑Guio A, Scheiner‑Bobis G, Schuler G, Shihan M, Wenzczycki C, Wudy SA, Bergmann M. The role of sulfated steroid hormones in reproductive processes. J Steroid Biochem Mol Biol. 2017;172:207–21.
17. Pasqualini JR, Chetrite G, Blacker C, Feinstein MC, Delalonde L, Talbi M, Maloche C. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab. 1996;81:1460–4.

18. Okuda T, Saito H, Sekizawa A, Shimizu Y, Akamatsu T, Kushima M, Yanaihara T, Okai T, Farina A. Steroid sulfatase expression in ovarian clear cell adenocarcinoma: immunohistochemical study. Gynecol Oncol. 2001;82:427–34.

19. Chura JC, Blomquist CH, Ryu HS, Argenta PA. Estrone sulfatase activity in patients with advanced ovarian cancer. Gynecol Oncol. 2009;112:205–9.

20. Mungenast F, Aust S, Versgote I, Vander星际chele A, Sehouli J, Braicu E, Mahner S, Castillo-Tong DC, Zeillinger R, Thalhammer T. Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer. OncoLett. 2017;13:4047–54.

21. Milewich L, Porter JC. In situ steroid sulfatase activity in human epithelial carcinoma cells of vaginal, ovarian, and endometrial origin. J Clin Endocrinol Metab. 1987;65:164–9.

22. Labrie F. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. J Steroid Biochem Mol Biol. 2015;145:133–8.

23. Labrie F, Luu-The V, Labrie C, Bélanger A, Simard J, Lin SX, Pelletier G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev. 2003;24:152–82.

24. Mizushima T, Miyamoto H. The role of androgen receptor signaling in ovarian cancer. Cells. 2019;8:176.

25. Suzuki T, Miki Y, Nakamura Y, Ito K, Sasano H. Steroid sulfatase and estrogen sulfotransferase in human carcinomas. Mol Cell Endocrinol. 2011;340:148–53.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.